Andreas Wallnöfer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team. Andreas is Partner at Jeito Capital a global leading European investment company. Prior to joining Jeito as Member of the Investment Committee in 2021, he was General Partner at BioMedPartners, a Swiss based venture capital firm.

Andreas has been successful as investor and in developing many innovative companies. He is and has been board member of several European biotech companies. Prior to his career in Venture, he has been Head of Cardiovascular & Metabolism R&D and member of the Roche / Genentech R&D Committee. Andreas was part of several successful product developments and market introductions. Before the integration of Genentech, Andreas was Global Head of Clinical Research & Exploratory Development and led the R&D organization at multiple sites in Europe, US and Asia. He had a key role in the integration of the Roche and Genentech Development organizations and led subsequently Roche’s Early Development Department.

Andreas is board member at CatalYm since 2022.

WordPress Cookie Notice by Real Cookie Banner